Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A sympathomimetic with alpha-adrenergic activity. It has a vasoconstrictor effect which reduces mucosal swelling and congestion.
Topical use via nasal spray (twice a day) or ophthalmological (3-4 times a day).
It is also used in face cream to treat rosacea (Kuang 2018) and, mixed with local anesthetics, in dental anesthesia.
Since the last update we have not found published data in relation to breastfeeding.
The small dose and low plasma absorption of most topical nasal, dermal or ophthalmological preparations make transfer into breastmilk in significant amounts unlikely.
Recorded plasma concentrations of oxymetazoline are low and their systemic effects are not clinically significant with the usual doses (Cartabuke 2019, Kuang 2018, Cacek 2017, Giannakopoulos 2012), so significant concentrations in milk are not expected.
Do not exceed the recommended dose and time periods in order to avoid undesirable side effects and the possible decrease in milk production cited by some authors (Nice 2000), but not proven in practice.
Expert authors consider the use of this medication to be safe and probably compatible during breastfeeding (Hale 2019, Briggs 2017, Anderson 2000).
Ophthalmic administration is fully compatible with breastfeeding. Absorption can be minimized by pressing on the tear duct (medial canthus of the eye) with your finger for 1 minute.
Some authors consider decongestant drugs administered orally and nasally to be non-essential medications, to be avoided in general, not only during breastfeeding, since they expose patients to serious risks (cardiovascular, neurological and intestinal) for the treatment of benign disorders such as nasal obstruction, which usually evolves favourably in a few days without medication (Prescrire 2018).
A mother reported irritability and insomnia for about 6 hours in her 7-month-old infant when she took oxymetazoline.